A team just won a battle in the war against antibiotic-resistant “superbugs” — and only time will tell if their feat will turn the tide toward victory. They won this particular battle, or at least gained critical intelligence, not by designing a new antibiotic, but by interfering with the metabolism of the bacterial “bugs” — E. coli in this case — and rendering them weaker in the face of existing antibiotics.